Autopsy report · NCT04002804

Immunotherapy With Autologous Tumor Lysate-Loaded Dendritic Cells In Patients With Recurrence Of Glioblastoma Multiforme

“Temozolomide does not favour immune response; secondary GBM to be excluded”

The sponsor’s own words in the registry.

Life of this trial

• Registered 9 years 2 months after it had already started.
• Ran for about 7 years 2 months before it stopped.
• 26 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

Sponsor type

University, hospital or other

Conditions

Glioblastoma

Interventions

Dendritic Cells Vaccine

Participants

26

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.